This report was first published by Endpoints News. To see the original version, click here
John Crowley, CEO of the trade group BIO, says he still supports FDA Commissioner Marty Makary even after a series of regulatory decisions on his watch have caused frustration and consternation among the biotech industry.
In an interview with Endpoints News on Tuesday, Crowley said the FDA “needs to continue to succeed” and that responsible regulatory risk is critical to fostering a healthy ecosystem for drug developers, particularly for rare disease treatments. He hasn’t seen as much of that.
您已阅读17%（587字），剩余83%（2825字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。